Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment

2018 ◽  
Vol 62 ◽  
pp. 299-308 ◽  
Author(s):  
Zhuanglin Li ◽  
Mingxue Wang ◽  
Xuejing Yao ◽  
Huanzhao Li ◽  
Shenjun Li ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Lymphoma Treatment ◽  
Antibody Drug

scholarly journals Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma

2020 ◽  
Vol 18 (8) ◽  
pp. 1125-1134
Author(s):  
Paul D. Harker-Murray ◽  
Lauren Pommert ◽  
Matthew J. Barth
Keyword(s):  
T Cell ◽  
B Cell ◽  
Targeted Therapies ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Acute Leukemias ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Antibody Drug

Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma are the most common aggressive pediatric mature B-cell non-Hodgkin lymphomas (B-NHLs). Despite excellent survival with current chemotherapy regimens, therapy for Burkitt lymphoma and DLBCL has a high incidence of short- and long-term toxicities. Patients who experience relapse generally have a very poor prognosis. Therefore, novel approaches using targeted therapies to reduce toxicities and improve outcomes in the relapse setting are needed. The addition of rituximab, a monoclonal antibody against CD20, to upfront therapy has improved survival outcomes for high-risk patients and may allow decreased total chemotherapy in those with low-risk disease. Antibody–drug conjugates have been combined with chemotherapy in relapsed/refractory (R/R) NHL, and multiple antibody–drug conjugates are in development. Additionally, bispecific T-cell–engaging antibody constructs and autologous CAR T-cells have been successful in the treatment of R/R acute leukemias and are now being applied to R/R B-NHL with some successes. PD-L1 and PD-L2 on tumor cells can be targeted with checkpoint inhibitors, which restore T-cell–mediated immunity and antitumor responses and can be added to conventional chemotherapy and immune-directed therapies to augment responses. Lastly, trials of small molecule inhibitors targeting cell signaling pathways in NHL subtypes are underway. This article reviews many of the targeted therapies under development that could be considered for future trials in R/R pediatric mature B-NHL.

scholarly journals Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Leukemia ◽  
2015 ◽  
Vol 29 (7) ◽  
pp. 1578-1586 ◽  
Author(s):  
M Pfeifer ◽  
B Zheng ◽  
T Erdmann ◽  
H Koeppen ◽  
R McCord ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Antibody Drug

scholarly journals Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yurou Chu ◽  
Xiangxiang Zhou ◽  
Xin Wang
Keyword(s):  
Therapeutic Index ◽  
Essential Elements ◽  
Brentuximab Vedotin ◽  
Efficacy And Safety ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Lymphoma Treatment ◽  
Novel Targets ◽  
Clinical Advances ◽  
Antibody Drug

AbstractAntibody-drug conjugates (ADCs) are a promising class of immunotherapies with the potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic drugs. ADCs comprise monoclonal antibodies, cytotoxic payloads with inherent antitumor activity, and specialized linkers connecting the two. In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment. As the efficacy and safety of ADCs have moved in synchrony with advances in their design, a plethora of novel ADCs have garnered growing interest as treatments. In this review, we provide an overview of the essential elements of ADC strategies in lymphoma and elucidate the up-to-date progress, current challenges, and novel targets of ADCs in this rapidly evolving field.

scholarly journals Retrospective Evaluation of Primary Mediastinal Large B Cell Lymphoma Treatment Results

LLM Dergi ◽  
2018 ◽  
Vol 2 (3) ◽  
pp. 60-64
Author(s):  
Erden ATİLLA ◽  
Pınar ATACA ATİLLA ◽  
Güldane CENGİZ SEVAL ◽  
Selami Koçak TOPRAK ◽  
Osman İLHAN ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Retrospective Evaluation ◽  
Treatment Results ◽  
Large B Cell Lymphoma ◽  
Lymphoma Treatment ◽  
Large B Cell

Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure

2018 ◽  
Vol 59 (12) ◽  
pp. 2896-2903 ◽  
Author(s):  
Ethan B. Ludmir ◽  
Sarah A. Milgrom ◽  
Chelsea C. Pinnix ◽  
Jillian R. Gunther ◽  
Jason Westin ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Treatment Strategies ◽  
B Cell Lymphoma ◽  
Patterns Of Failure ◽  
Large B Cell Lymphoma ◽  
Lymphoma Treatment ◽  
Large B Cell

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

NEJM Evidence ◽  
2021 ◽  
Author(s):  
Michael L. Wang ◽  
Jacqueline C. Barrientos ◽  
Richard R. Furman ◽  
Matthew Mei ◽  
Paul M. Barr ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Phase 1 ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Mantle Cell ◽  
Large B Cell ◽  
Antibody Drug ◽  
Drug Complex

In a phase 1 trial involving patients with refractory lymphoid cancer, an antibody-drug complex directed against ROR1 had no unexpected toxicities. About half of the patients with mantle cell lymphoma and diffuse large B-cell lymphoma had clinically meaningful responses.

Sign in / Sign up

Export Citation Format

Share Document